Glyphmet M2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 500 mg, formulated for sustained release to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The sustained-release formulation allows for gradual drug release, minimizing gastrointestinal side effects commonly associated with metformin and promoting better patient compliance through once-daily dosing. Glyphmet M2 is indicated as an adjunct to diet and exercise to improve glycemic control in adults when monotherapy with either agent is inadequate. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoglycemia. Contraindications include diabetic ketoacidosis, severe renal or hepatic disease, and hypersensitivity to components. Adverse effects may include hypoglycemia, gastrointestinal disturbances, and rarely lactic acidosis. Patient education on adherence, lifestyle modification, and recognition of hypoglycemia symptoms is crucial for optimal outcomes.